Results 121 to 130 of about 590,194 (288)

Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine

mBio, 2018
Bivalent rLP2086 (Trumenba), a vaccine for prevention of Neisseria meningitidis serogroup B (NmB) disease, was licensed for use in adolescents and young adults after it was demonstrated that it elicits antibodies that initiate complement-mediated killing
L. Mcneil, R. Donald, A. Gribenko, R. French, N. Lambert, S. Harris, T. Jones, Sheng Li, G. Zlotnick, U. Vogel, H. Claus, R. Abad, J. Vázquez, R. Borrow, J. Findlow, M. Taha, A. Deghmane, D. Caugant, P. Kriz, M. Musílek, Xin Wang, Jeni T. Vuong, L. Mayer, M. Pride, K. Jansen, A. Anderson   +25 more
semanticscholar   +1 more source

Increased risk of bacterial pneumonia before and after respiratory syncytial virus infection in young children

Acta Paediatrica, Volume 114, Issue 1, Page 83-91, January 2025.
Abstract Aim The burden of respiratory disease is great among children. This study aimed to examine the temporal relationship between hospitalisation for respiratory syncytial virus (RSV) and bacterial pneumonia. Methods A Swedish population‐based cohort was created by combining data from the Swedish Medical Birth Register, the National Inpatient ...
Karin Strandell, Samuel Videholm, Andreas Tornevi, Maria Björmsjö, Sven Arne Silfverdal   +4 more
wiley   +1 more source

Trends in Meningococcal Disease in the United States Military, 1971–2010

Emerging Infectious Diseases, 2012
Meningococci have historically caused extensive illness among members of the United States military. Three successive meningococcal vaccine types were used from 1971 through 2010; overall disease incidence dropped by >90% during this period.
Michael P. Broderick, Dennis J. Faix, Christian J. Hansen, Patrick J. Blair   +3 more
doaj   +1 more source

Communication Challenges During the Development and Introduction of a New Meningococcal Vaccine in Africa

Clinical Infectious Diseases, 2015
Background. A new group A meningococcal conjugate vaccine was developed to eliminate deadly meningitis epidemics in sub-Saharan Africa. Methods. From the outset of the project, advocacy and communication strategies were developed and adjusted as the ...
M. Berlier, R. Barry, J. Shadid, C. Sirica, A. Brunier, H. Hasan, E. Bouma   +6 more
semanticscholar   +1 more source

Invasive Meningococcal Disease in the Vaccine Era

Frontiers in Pediatrics, 2018
Infection with the meningococcus is one of the main causes of meningitis and septicaemia worldwide. Humans are the only natural reservoir for the meningococcus which is found primarily as a commensal inhabitant in the nasopharynx in ~10% of adults, and ...
S. Nadel, N. Ninis
semanticscholar   +1 more source

Prevalence of de-O-acetylated serogroup C meningococci before the introduction of meningococcal serogroup C conjugate vaccines in the United Kingdom [PDF]

, 2000
Ray Borrow, Emma Longworth, Stephen J. Gray, Edward B. Kaczmarski   +3 more
openalex   +2 more sources

A Meningococcal Outer Membrane Vesicle Vaccine with Overexpressed Mutant FHbp Elicits Higher Protective Antibody Responses in Infant Rhesus Macaques than a Licensed Serogroup B Vaccine

mBio, 2019
There are two licensed meningococcal capsular B vaccines. Both contain recombinant factor H binding protein (FHbp), which can bind to host complement factor H (FH). The limitations of these vaccines include a lack of protection against some meningococcal
P. Beernink, Vianca V Vianzon, L. Lewis, G. Moe, D. Granoff   +4 more
semanticscholar   +1 more source

A meningococcal B vaccine induces cross-protection against gonorrhea

Clinical and experimental vaccine research, 2019
Purpose Neisseria meningitidis and Neisseria gonorrhoeae share between 80% and 90% of their genetic sequence. Meningococcal serogroup B vaccines based on outer membrane vesicles—such as VA-MENGOC-BC—could cross-protect against gonorrhea.
Rolando Felipe Ochoa Azze
semanticscholar   +1 more source

Critical appraisal of a quadrivalent CRM197 conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo®) in the context of treatment and prevention of invasive disease

Infection and Drug Resistance, 2011
Michael Bröker, Brian Cooper, Lisa M DeTora, Jeffrey J StoddardGlobal Medical Affairs, Novartis Vaccines and Diagnostics, Marburg, Germany, and Cambridge, MA, USAAbstract: Worldwide, invasive meningococcal disease affects about 500,000 people ...
Bröker M, Cooper B, DeTora LM, Stoddard JJ   +3 more
doaj  

Statistics of infections with diversity in the pathogenicity [PDF]

arXiv, 2004
The statistics of outbreaks in a model for the propagation of meningococcal diseases is analyzed, taking into account the possibility that the population is fragmented into weakly connected patches. It is shown that, depending on the size of of the sample studied, the ratio between the variance and the mean of infected cases can vary from one (Poisson ...
arxiv